ECM
CDLX icon

ETrade Capital Management’s Cardlytics CDLX Stock Holding History

ETrade Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$589K Sell
835
-26
-3% -$18.9K 0.01% 521
2020
Q2 		$603K Buy
+861
New +$497K 0.01% 498

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ETrade Capital Management's CDLX Position: Q3 2020 in Review

ETrade Capital Management reduced its Cardlytics (CDLX) stake by 3% in Q3 2020, selling an estimated $18.9K and leaving 835 shares worth $589K. The position accounts for 0.01% of the portfolio, ranked #521.

ETrade Capital Management first reported a position in CDLX in Q2 2020 and has held it in 2 quarters since. The position peaked at $603K in Q2 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2020.

  • ETrade Capital Management held 835 shares of Cardlytics worth $589K as of Q3 2020.
  • ETrade Capital Management sold 26 Cardlytics shares in Q3 2020, an estimated $18.9K.
  • Cardlytics made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #521 holding.
  • ETrade Capital Management first reported a position in Cardlytics in Q2 2020 and has held it in 2 quarters since.
  • ETrade Capital Management's Cardlytics position peaked at $603K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.